TG Therapeutics Community
Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Consensus Narrative from 8 Analysts
BRIUMVI’s Success Will Drive Future Expansion In The MS Market
Key Takeaways Successful BRIUMVI launch, strong data, and label updates could boost revenue and positioning in the MS market. Development of subcutaneous BRIUMVI and CAR-T therapy may drive market expansion and portfolio diversification.
View narrativeUS$40.75
FV
21.1% undervalued intrinsic discount56.39%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Updated narrative